Fasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...

Can you do it? Can you ace these quiz questions about EGPA? They’re all derived from the current literature. At the end of the quiz, compare your score with those of your physician colleagues.

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

and Nucala might be part of the initial treatment for nonsevere EGPA-type vasculitis (eosinophilic granulomatosis with polyangiitis vasculitis). Rituxan is also an important example. It might be used, ...

The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...

Depemokimab is also being evaluated in late-stage studies for eosinophilic granulomatosis with polyangiitis and hyper-eosinophilic syndrome. Sales in GSK’s respiratory portfolio are currently ...

It can now also be used as an add-on treatment in adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). Its original indication is as an add-on maintenance ...

Amyloidosis. StatPearls Publishing; 2023. American Lung Association. Learn About Eosinophilic Granulomatosis with Polyangiitis (EGPA). National Institute of Arthritis and Musculoskeletal and Skin ...

Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...